BridgeMD
Compares treatment options for Chronic Hepatitis D
Official title Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
ClinicalTrials.gov ID: NCT07454837
What this study is testing
What is Brelovitug (BJT-778)?
Brelovitug (BJT-778) is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for chronic hepatitis d.
Also referred to as BJT-778.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Willing and able to provide written informed consent.
- Male or female, ≥18 years of age at Screening.
- Taking or willing to take TDF, TAF, or ETV at baseline, and willing to remain on stable treatment for the duration of the study.
- Currently taking bulevirtide treatment for CHD for ≥6 months at the time of Screening.
- HDV RNA ≥100 IU/mL at Screening.
You likely can't join if
- Evidence of decompensated liver disease (e.g., CTP Class B or C, history of hepatic encephalopathy, clinically significant ascites, or variceal...
- Known history of immune-complex disease.
- Active or clinically significant co-infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
- Evidence of other significant liver diseases (e.g., autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis).
- History of hepatocellular carcinoma (HCC) or evidence of HCC on screening imaging.
The study team makes the final eligibility decision.
Where it's taking place
- Graz, Austria
- Innsbruck, Austria
- Brno, Czechia
- Prague, Czechia
- Bordeaux, France
- Clermont-Ferrand, France
- Clichy, France
- Créteil, France
- Grenoble, France
- Limoges, France
- Lyon, France
- Montpellier, France
- Paris, France
- Toulouse, France
- Düsseldorf, Germany
- Frankfurt, Germany
- Hanover, Germany
- Rostock, Germany
- Milan, Italy
- Iași, Lasi, Romania
+ 8 more site(s).
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Graz, Austria; Innsbruck, Austria; Brno, Czechia; Prague, Czechia; Bordeaux, France; Clermont-Ferrand, France and 22 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.